These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 25831681)
21. Botulinum toxin a for idiopathic detrusor overactivity. Lie KY; Wong MY; Ng LG Ann Acad Med Singap; 2010 Sep; 39(9):714-5. PubMed ID: 20957307 [TBL] [Abstract][Full Text] [Related]
22. [Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome]. Deffieux X; Fatton B; Denys P; Chartier-Kastler E; Amarenco G; Haab F; Costa P; Game X; Karsenty G; Saussine C; Ballanger P; Le Normand L; Ruffion A; Hermieu JF; Cosson M J Gynecol Obstet Biol Reprod (Paris); 2014 Oct; 43(8):572-80. PubMed ID: 25087018 [TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin treatment for bladder dysfunction. Santos-Silva A; da Silva CM; Cruz F Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720 [TBL] [Abstract][Full Text] [Related]
25. Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. Abrar M; Pindoria N; Malde S; Chancellor M; DeRidder D; Sahai A Eur Urol Focus; 2021 Nov; 7(6):1448-1467. PubMed ID: 32616412 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. Sahai A; Khan MS; Dasgupta P J Urol; 2007 Jun; 177(6):2231-6. PubMed ID: 17509328 [TBL] [Abstract][Full Text] [Related]
27. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study. Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110 [TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Gamé X; Mouracade P; Chartier-Kastler E; Viehweger E; Moog R; Amarenco G; Denys P; De Seze M; Haab F; Karsenty G; Kerdraon J; Perrouin-Verbe B; Ruffion A; Soler JM; Saussine C J Pediatr Urol; 2009 Jun; 5(3):156-64. PubMed ID: 19264554 [TBL] [Abstract][Full Text] [Related]
29. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. Sahai A; Dowson C; Khan MS; Dasgupta P BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019 [TBL] [Abstract][Full Text] [Related]
30. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease. Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449 [TBL] [Abstract][Full Text] [Related]
31. Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes. Okamura K; Nojiri Y; Ameda K; Namima T; Suzuki M; Inoue K; Ogawa T; Gotoh M; Homma Y Int J Urol; 2011 Jun; 18(6):483-7. PubMed ID: 21488978 [TBL] [Abstract][Full Text] [Related]
32. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Cohen BL; Barboglio P; Rodriguez D; Gousse AE Neurourol Urodyn; 2009; 28(3):205-8. PubMed ID: 19058190 [TBL] [Abstract][Full Text] [Related]
33. Botulinum neurotoxin A for overactive bladder treatment: advantages and pitfalls. Chibelean C; Nechifor-Boila IA Can J Urol; 2015 Apr; 22(2):7681-9. PubMed ID: 25891330 [TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298 [TBL] [Abstract][Full Text] [Related]
35. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396 [TBL] [Abstract][Full Text] [Related]
36. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. Anger JT; Weinberg A; Suttorp MJ; Litwin MS; Shekelle PG J Urol; 2010 Jun; 183(6):2258-64. PubMed ID: 20400142 [TBL] [Abstract][Full Text] [Related]
37. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy. Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028 [TBL] [Abstract][Full Text] [Related]
38. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Cruz F; Nitti V Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140 [TBL] [Abstract][Full Text] [Related]
39. An indirect comparison meta-analysis of noninvasive intravesical instillation and intravesical injection of botulinum toxin-A in bladder disorders. Yunfeng G; Fei L; Junbo L; Dingyuan Y; Chaoyou H Int Urol Nephrol; 2022 Mar; 54(3):479-491. PubMed ID: 35044552 [TBL] [Abstract][Full Text] [Related]
40. Intravesical Botulinum toxin-A injection in pediatric overactive neurogenic bladder with Detrusor overactivity: Radiologic and clinical outcomes. Sharifiaghdas F; Narouie B; Rostaminejad N; Hamidi Madani M; Manteghi M; Rouientan H; Ahmadzade M; Dadpour M Urologia; 2023 May; 90(2):357-364. PubMed ID: 36404763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]